Nephroprotection of an ET(A)-receptor blocker (LU 135252) in salt- loaded uninephrectomized stroke-prone spontaneously hypertensive rats

Hypertension

Volumn 31, Issue 4, 1998, Pages 995-1001

  Orth, Stephan R ^a   Esslinger, Jan P ^b   Amann, Kerstin ^b   Schwarz, Ute ^b   Raschack, Manfred ^b   Ritz, Eberhard ^b  

^a Medizinische Klinik I   (Germany)

^b NONE

Author keywords

Endothelin kidney; Rats, inbred SHRsp; Receptors, endothelin; Renal failure

Indexed keywords

DARUSENTAN; ENDOTHELIN A RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERTENSION; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; UNINEPHRECTOMY;

EID: 0031900281     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.31.4.995     Document Type: Article

References (39)

1. Simonson MS. Endothelin peptides and compensatory growth of renal cells. Curr Opin Nephrol Hypertens. 1994;3:73-85.
2. Benigni A, Perico N, Gaspari F, Zoja C, Bellizzi L, Gabanelli M, Remuzzi G. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol. 1991;260:F33I-F339.
3. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 1993;43: 354-358.
4. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.
5. Nabokov A, Amann K, Wagner J, Gehlen F, Münter K, Ritz E. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant. 1996;11:514-520.
6. Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int. 1995; 47:481-489.
7. Fukuda K, Yanagida T, Okuda S, Tamaki K, Ando T, Fujishima M. Role of endothelin as a mitogen in experimental glomerulonephritis in rats. Kidney Int. 1996;49:1320-1329.
8. Nakamura T, Ebihara I, Tomino Y, Koide H. Alteration of growth-related proto-oncogene expression in diabetic glomeruli by a specific endothelin receptor A antagonist. Nephrol Dial Transplant. 1496;11: 1528-1531.
9. Hendry BM, James AF. Endothelin antagonists in renal disease. Lancet. 1997;350:381-382.
10. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K, Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ123, in a genetic hypertensive model. Life Sci. 1993;52:717-724.
11. Hocher B, Rohmeiss P, Zart R, Diekmann F, Vogt V, Metz D, Fakhury M, Gretz N, Bauer C, Koppenhagen K, Neumayer HH, Distler A. Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc Res. 1996;31: 499-510.
12. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol. 1995;114:925-930.
13. Douglas SA, Gellai M, Ezekiel M, Feuerstein GZ, Elliott JD, Ohlstein EH. Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension. 1995;25(pt 2):818-822.
14. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M, Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ET-A receptor. Life Sci. 1992;50:247-255.
15. Clozel M, Breu V, Gray GA, Kalina B, Löffler B-M, Burri K, Cassal J-M, Hirth G, Müller M, Niedhart W, Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270:228-235.
16. Hocher B, Rohmeiss P, Diekmann F, Zarr R, Vogt V, Schiller S, Bauer C, Koppenhagen K, Distler A, Gretz N. Distribution of endothelin receptor subtypes in the rat kidney: renal and haemodynamic effects of the mixed (A/B) endothelin receptor antagonist bosentan. Eur J Clin Chem Clin Biochem. 1995;33:463-472.
17. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Lüscher TF. Oxidized low-density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70: 1191-1197.
18. Li J-S, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension. 1995;25(pt 1):495-500.
19. Stumpf Ch, Goeck S, Unger L, Nebel M, Riechers H, Raschack M. LU 135 252 shows high endothelin-A receptor affinity and selectivity and oral efficacy leading to reduction of neointima formation in collared rabbit carotid arteries. Naunyn Schmiedeberg Arch Pharmacol. 1997; 355(suppl):R103. Abstract.
20. Amann K, Irzyniec T, Mall G, Ritz E. The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy: a stereological study. J Hypertens. 1993;11:969-975.
21. Hughes AK, Cline RC, Kohan DE. Alteration of renal endothelin-1 production in the spontaneously hypertensive rat. Hypertension, 1992;20: 666-673.
22. Doucet J, Gonzalez W, Michel JB. Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol. 1996;27:643-651.
23. Hocher B, Liefeldt L, Thöne-Reineke C, Orzechowski H-D, Distler A, Bauer C, Paul M. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension. 1996;28: 196-201.
24. Largo R, Gómez-Garre D, Liu XH, Alonso J, Blanco J, Plaza JJ, Egido J. Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril. Hypertension. 1997;29:1178-1185.
25. Zoja C, Corna D, Bruzzi I, Foglieni C, Bertani T, Remuzzi G, Benigni A. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp Nephrol. 1996;4:213-221.
26. Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T, Tomita K, Marumo F. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int. 1991;39:307-311.
27. Feron O, Salomone S, Godfraind T. Influence of salt loading on the cardiac and renal preproendothelin-1 mRNA expression in stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun. 1995; 209:161-166.
28. Gellai M, DeWolf R, Pullen M, Nambi P. Distribution and role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney Int. 1994;46:1287-1294.
29. Simonson MS, Wann S, Mené P, Dubyak GR, Kester M, Nakazato Y, Sedor JR, Dunn MJ. Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest. 1989;83:708-712.
30. Jaffer FE, Knauss TC, Poptic E, Abboud HE. Endothelin stimulates PDGF secretion in cultured human mesangial cells. Kidney Int. 1990;38: 1193-1198.
31. Ruíz-Ortega M, Gómez-Garre D, Alcázar R, Palacios I, Bustos C, González S, Plaza JJ, González E, Egido J. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens. 1994;12(suppl 4):S51-S58.
32. Takemoto F, Uchida S, Ogata E, Kurokawa K. Endothelin-1 and endothelin-3 binding to rat nephrons. Am J Physiol. 1993;264: F827-F832.
33. Kivlighn SD, Gabel RA, Siegl PK. Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction. Kidney Int. 1994;45:131-136.
34. Ong ACM. Tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Nephrol Dial Transplant. 1996;11:251-257.
35. Terada Y, Tomita K, Nonoguchi H, Marumo F. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction. J Clin Invest. 1992;90:107-112.
36. Silldorf EP, Yang S, Pallone TL. Prostaglandin E2 abrogates endothelin-induced vasoconstriction in renal outer medullary descending vasa recta of the rat. J Clin Invest. 1995;95:2734-2740.
37. Ong ACM, Jowett TP, Firth JD, Burton S, Kitamura M, Fine LG. A new paracrine loop implicated in human tubulointerstitial disease: tubular-derived endothelins modulate renal interstitial fibroblast function. J Am Soc Nephrol. 1993;4:473. Abstract.
38. Achmad T, Rao G. Chemotaxis of human blood monocytes towards endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun. 1992;189:994-1000.
39. A receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol. 1992;225:347-350.